Abatacept Clinical Trial Program (N = 4134) | BC (N = 12 337) | NDB (N = 10 499) | GPRD (N = 14 467) | NOAR (N = 523) | Sweden ERA (N = 3703) | |
Age, years, n (%) | ||||||
<20 | 4 (0.1) | 214 (2) | 13 (0.1) | 34 (0.2) | 3 (1) | 29 (1) |
20–44 | 1011 (24) | 2874 (23) | 1429 (14) | 2856 (20) | 106 (20) | 753 (20) |
45–64 | 2435 (59) | 5148 (42) | 4870 (47) | 6998 (48) | 246 (47) | 1624 (44) |
65–74 | 553 (13) | 2692 (22) | 2716 (26) | 3375 (23) | 120 (23) | 797 (22) |
⩾75 | 131 (3) | 1409 (11) | 1438 (14) | 1204 (8) | 48 (9) | 500 (14) |
Female, n (%) | 3323 (80) | 8936 (72) | 7971 (76) | 10 284 (71) | 357 (68) | 2589 (70) |
Duration of RA, years, n (%) | ||||||
<5 | 1353 (33) | 4890 (40) | 2726 (29)* | NA | 523 | 3703 |
5–10 | 1192 (29) | 4206 (34) | 1902 (20)* | NA | 0 | 0 |
>10 | 1586 (38) | 3241 (26) | 4716 (50)* | NA | 0 | 0 |
Concomitant medications, n (%)† | ||||||
Oral corticosteroids | 2657 (64) | 8121 (66) | NA | 6902 (48) | 194 (37) | NA |
NSAID | 3113 (75) | 11 001 (89) | 6820 (65) | 13 656 (94) | 416 (80) | NA |
Total follow-up, years | ||||||
Mean | 2.1 | 4.9 | 3.3 | 3.7 | 7.9 | 3.6 |
Median | 1.8 | 6.0 | 2.5 | 4.1 | 9.3 | NA |
*Rheumatoid arthritis (RA) duration was not collected for every subject in the NDB; therefore, n = 9344 for this variable. †Use of concomitant medications at baseline is presented for the abatacept trial population, whereas use during follow-up is presented for the RA cohorts (when available).
BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; NDB, National Data Bank for Rheumatic Diseases; NOAR, Norfolk Arthritis Register; NSAID, non-steroidal anti-inflammatory drugs; Sweden ERA, Sweden Early Rheumatoid Arthritis Register.